Morgan Stanley maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and lowers the price target from $315 to $213.
Morgan Stanley Maintains Equal-Weight on Moderna, Lowers Price Target to $213
Morgan Stanley maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and lowers the price target from $315 to $213.
Related Posts
Backlash Against Spotify Star Joe Rogan Intensifies, Now Over Racial Slur
Spotify Technology SA's (NYSE: SPOT) top podcaster Joe Rogan over the weekend apologized for using a racial slur on previous episodes of his show as the company removed over 100 episodes of the “Joe Rogan Experience,” according to JRE
Provident Financial Hldgs Q3 EPS $0.23, Inline
Provident Financial Hldgs (NASDAQ:PROV) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 9.52 percent increase over earnings of $0.21 per share from the same period last
Piper Sandler Initiates Coverage On NeoGenomics with Overweight Rating, Announces Price Target of $13
Piper Sandler analyst David Westenberg initiates coverage on NeoGenomics (NASDAQ:NEO) with a Overweight rating and announces Price Target of $13.